This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
Kidney Cancer
RadiCal
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
FORT
NRG-GU 0101
Masofaniten (Oral EPI-7386)
RTIRE
SHORTER
SPLASH
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Suprapubic Catheter
Diane K. Newman, DNP FAAN BCB-PMD
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AMA Interim 2023
SUO 2023
ESMO 2023
IBCN 2023
ASTRO 2023
All Conferences
View All
PCF
UroToday Home
Video Lectures
ASCO GU 2022
ASCO GU 2022 VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky
Details
Alicia Morgans and Matthew Galsky discuss a two-part open-label study of trastuzumab deruxtecan with nivolumab in patients with HER2 expressing urothelial carcinoma. Dr. Galsky provides background on the rise of combination therapies of antibody-drug conjugates and immune checkpoint blockades in urothelial cancer. They also discuss the preliminary success of this combination therapy and that we wi...
Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
Details
Daniel Spratt and Jeff Michalski discuss the pivotal NRG Oncology RTOG 0126 trial from which Dr Michalski is the PI. This phase III randomized NRG/RTOG 0126 trial provides the first validation of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer. Dr. Spratt provides the background on the rationale for the NRG/RTOG 0126 and the results from the RTOG 0126 trial. They discus...
First Results of MAGNITUDE – Niraparib with Abiraterone Acetate and Prednisone a First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Kim Chi
Details
Alicia Morgans speaks with Kim Chi about the MAGNITUDE trial presented at GU ASCO 2022. The Phase III trial investigates the efficacy of combining niraparib, a PARP inhibitor, with abiraterone and prednisone in treating metastatic castration-resistant prostate cancer (mCRPC). The study focuses on patients with and without homologous recombination repair (HRR) gene alterations. Results reveal that...
Highlights In Urothelial Carcinoma at GU ASCO 2022 - Guru Sonpavde
Details
Ashish Kamat hosts Guru Sonpavde to discuss key findings from the GU ASCO symposium. Dr. Sonpavde reviews a range of groundbreaking studies, emphasizing the potential of systemic therapy for metastatic bladder cancer. Noteworthy trials include TROPHY-U-01, which shows a 34% response rate combining sacituzumab govitecan with pembrolizumab, and a study on neoadjuvant enfortumab vedotin revealing a 3...
Sacituzumab Govitecan in Combination with Pembrolizumab in Metastatic Urothelial Cancer - Petros Grivas
Details
Alicia Morgans talks with Petros Grivas about the TROPHY-U-01 study, which evaluates the efficacy of combining Sacituzumab govitecan (SG) with anti-PD-1 pembrolizumab in patients with platinum-refractory advanced urothelial cancer. Dr. Grivas elaborates on the study's rationale, citing SG's FDA approval based on a 27% response rate and tolerability. The study aims to explore the potential benefits...
Next-Generation Sequencing: Discussing Results with Patients - Bishoy Faltas
Details
Alicia Morgans and Bishoy Faltas delve into the complexities and nuances of Next-Generation Sequencing (NGS) in clinical practice. Dr. Faltas emphasizes the importance of understanding the technical aspects of NGS, such as the type of sequencing and the coverage, to interpret results accurately. He also highlights the need for clinicians to be aware of the computational analysis that NGS undergoes...
Anticipated Data from Transformative Trials at ASCO GU 2022 - Oliver Sartor
Details
Alicia Morgans and Oliver Sartor discuss the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on Feb 17-20, 2022, and the data from key presentations in prostate cancer, bladder cancer, and kidney cancer. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Director, Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Resear...
Start
Prev
1
2
3
4
5
6
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free